Mereo BioPharma Group plc

US$0.28As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MREOHealthcare
Country USA
PE (Fwd) •••
TSR 8Y CAGR (32.74%)
Div yield —
ROE (67.85%)
Biotechnology
Beta (5Y) 0.20
PE TTM —
TSR TTM (85.11%)
Mkt cap US$45.19M
ROIC (48.94%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.311
9.87%
(83.59%)
Sell 3|7|6|4|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
—
—
—
0.01
17.78%
19.87%
16.24%
19.31%
Revenue$M
2.716
2.856
2.876
3.010
(5.15%)
2.24%
2.18%
8.43%
Peers (US$45.19M)
Cap (US$)
PE
39.28M
—
45.23M
26.89x
Capital
TTM
5Y
10Y
Leveragex
1.268
0.409
0.304
EBIT/Intx
0.678
0.104
0.109
Own earn%
(779.31)
48.59
47.97
Sh yield%
46.05
15.95
15.51
Owners
Insiders/Inst%
6.52
53.55
Short interest%
5.93
SBC / revenue%
2.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
6–14
$1 testx
0.2
Incr. ROIC%
1